CA2330055A1 - Paroxetine ascorbate - Google Patents

Paroxetine ascorbate Download PDF

Info

Publication number
CA2330055A1
CA2330055A1 CA002330055A CA2330055A CA2330055A1 CA 2330055 A1 CA2330055 A1 CA 2330055A1 CA 002330055 A CA002330055 A CA 002330055A CA 2330055 A CA2330055 A CA 2330055A CA 2330055 A1 CA2330055 A1 CA 2330055A1
Authority
CA
Canada
Prior art keywords
paroxetine
ascorbate
salt
solution
paroxetine ascorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002330055A
Other languages
English (en)
French (fr)
Inventor
Michael Urquhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2330055A1 publication Critical patent/CA2330055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002330055A 1998-04-25 1999-04-23 Paroxetine ascorbate Abandoned CA2330055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound
GB9808896.6 1998-04-25
PCT/GB1999/001244 WO1999055698A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Publications (1)

Publication Number Publication Date
CA2330055A1 true CA2330055A1 (en) 1999-11-04

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002330055A Abandoned CA2330055A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Country Status (20)

Country Link
EP (1) EP1089995A1 (xx)
JP (1) JP2002513019A (xx)
KR (1) KR20010042977A (xx)
CN (1) CN1297448A (xx)
AP (1) AP2000001963A0 (xx)
AU (1) AU3618499A (xx)
BG (1) BG104940A (xx)
BR (1) BR9909868A (xx)
CA (1) CA2330055A1 (xx)
EA (1) EA200001104A1 (xx)
GB (1) GB9808896D0 (xx)
HU (1) HUP0102116A3 (xx)
ID (2) ID26083A (xx)
IL (1) IL139081A0 (xx)
NO (1) NO20005352L (xx)
PL (1) PL343677A1 (xx)
SK (1) SK15912000A3 (xx)
TR (1) TR200003084T2 (xx)
WO (1) WO1999055698A1 (xx)
ZA (1) ZA200005912B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
EP2272501B1 (en) * 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
CN110607554B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.

Also Published As

Publication number Publication date
ID26654A (id) 2001-01-25
TR200003084T2 (tr) 2001-02-21
HUP0102116A2 (hu) 2002-05-29
SK15912000A3 (sk) 2001-04-09
KR20010042977A (ko) 2001-05-25
ID26083A (id) 2000-11-23
BR9909868A (pt) 2000-12-19
BG104940A (bg) 2001-09-28
EP1089995A1 (en) 2001-04-11
NO20005352D0 (no) 2000-10-24
IL139081A0 (en) 2001-11-25
WO1999055698A1 (en) 1999-11-04
GB9808896D0 (en) 1998-06-24
JP2002513019A (ja) 2002-05-08
CN1297448A (zh) 2001-05-30
EA200001104A1 (ru) 2001-04-23
ZA200005912B (en) 2001-12-19
NO20005352L (no) 2000-10-24
AU3618499A (en) 1999-11-16
PL343677A1 (en) 2001-08-27
HUP0102116A3 (en) 2002-12-28
AP2000001963A0 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
US20040242506A1 (en) Paroxetine glycyrrhizinate
CA2319652A1 (en) Salts of paroxetine
WO2000035873A1 (en) Process for preparation of paroxetine maleate
CA2327450A1 (en) Paroxetine maleate
CA2330055A1 (en) Paroxetine ascorbate
AU3618699A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00010439A (en) Paroxetine ascorbate
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
US20030028027A1 (en) Paroxetine maleate
CZ20003942A3 (cs) Askorbat paroxetinu
AU2528899A (en) Salts of paroxetine
MXPA00009884A (en) Paroxetine maleate
WO2001014369A2 (en) Process for the preparation of paroxetin.hcl
WO2001025230A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
EP1408039A2 (en) Mixed paraxetine propan-2-ol solvates
CZ20003722A3 (cs) Maleat paroxetinu
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
CZ20003941A3 (cs) 10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému
MXPA00007719A (en) Salts of paroxetine
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
WO2001025231A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
WO2001025232A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
WO2000032596A1 (en) Amine salts of paroxetine

Legal Events

Date Code Title Description
FZDE Discontinued